| Elucidation of relationship between tumor size and survival in non‐small‐cell lung cancer patients can aid early decision making in clinical drug development Y Wang, C Sung, C Dartois, R Ramchandani, BP Booth, E Rock, ... Clinical Pharmacology & Therapeutics 86 (2), 167-174, 2009 | 233 | 2009 |
| Are population pharmacokinetic and/or pharmacodynamic models adequately evaluated? K Brendel, C Dartois, E Comets, A Lemenuel-Diot, C Laveille, ... Clinical pharmacokinetics 46 (3), 221-234, 2007 | 214 | 2007 |
| Phase I dose-escalation and-expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors J Rodon, I Braña, LL Siu, MJ De Jonge, N Homji, D Mills, E Di Tomaso, ... Investigational new drugs 32 (4), 670-681, 2014 | 197 | 2014 |
| A review of mixed‐effects models of tumor growth and effects of anticancer drug treatment used in population analysis B Ribba, NH Holford, P Magni, I Trocóniz, I Gueorguieva, P Girard, C Sarr, ... CPT: pharmacometrics & systems pharmacology 3 (5), 1-10, 2014 | 188 | 2014 |
| Overview of model‐building strategies in population PK/PD analyses: 2002–2004 literature survey C Dartois, K Brendel, E Comets, CM Laffont, C Laveille, B Tranchand, ... British journal of clinical pharmacology 64 (5), 603-612, 2007 | 105 | 2007 |
| A Dynamic Model of Hand‐and‐Foot Syndrome in Patients Receiving Capecitabine E Hénin, B You, E VanCutsem, PM Hoff, J Cassidy, C Twelves, ... Clinical Pharmacology & Therapeutics 85 (4), 418-425, 2009 | 54 | 2009 |
| Evaluation of uncertainty parameters estimated by different population PK software and methods C Dartois, A Lemenuel-Diot, C Laveille, B Tranchand, M Tod, P Girard Journal of pharmacokinetics and pharmacodynamics 34 (3), 289-311, 2007 | 46 | 2007 |
| Pharmacometrics Markup Language (PharmML): opening new perspectives for model exchange in drug development MJ Swat, S Moodie, SM Wimalaratne, NR Kristensen, M Lavielle, A Mari, ... CPT: pharmacometrics & systems pharmacology 4 (6), 316-319, 2015 | 41 | 2015 |
| Dynamic tumor modeling of the dose–response relationship for everolimus in metastatic renal cell carcinoma using data from the phase 3 RECORD-1 trial A Stein, W Wang, AA Carter, O Chiparus, N Hollaender, H Kim, RJ Motzer, ... BMC cancer 12 (1), 311, 2012 | 40 | 2012 |
| Exposure-effect population model of inolimomab, a monoclonal antibody administered in first-line treatment for acute graft-versus-host disease C Dartois, G Freyer, M Michallet, E Hénin, B You, I Darlavoix, ... Clinical pharmacokinetics 46 (5), 417-432, 2007 | 15 | 2007 |
| Clinical importance of including new and nontarget lesion assessment of disease progression (PD) to predict overall survival (OS): Implications for randomized phase II study … WL Mietlowski, W Bao, PA Wood, DE Williams, M El-Hashimy, C Sarr, ... ASCO Annual Meeting Proceedings 30 (15_suppl), 2543, 2012 | 4 | 2012 |
| A phase I dose escalation and expansion trial of BKM120, an oral pan-PI3K inhibitor, in patients with advanced solid tumors: analysis of pharmacodynamic biomarker data J Rodon, J Bendell, ARA Razak, MJA De Jonge, F Eskens, E Di Tomaso, ... ANNALS OF ONCOLOGY 23, 158-159, 2012 | 3 | 2012 |
| Quantifying the effect of everolimus on both tumor growth and new metastases in metastatic renal cell carcinoma (RCC): A dynamic tumor model of the RECORD-1 phase III trial. AM Stein, A Carter, N Hollaender, RJ Motzer, C Sarr ASCO Annual Meeting Proceedings 29 (15_suppl), 4602, 2011 | 3 | 2011 |
| Population pharmacokinetic analysis of peginterferon alfa-2a (40KD) supports use of BSA-category based dosing in children with chronic hepatitis B: PEG-B-ACTIVE pharmacokinetic … C Sarr, H Deng, E Snoeck, H Zhang, N Assy, Y Lobzin, A Potapov, ... Hepatology 63, 929A, 2016 | 2 | 2016 |
| Clinical pharmacokinetic-pharmacodynamic (PK/PD) modeling study of the novel dual PI3K/mTOR inhibitor BEZ235. D Bottino, J Tabernero, HA Burris, C Britten, LC Chen, JC Bendell, ... ASCO Annual Meeting Proceedings 29 (15_suppl), 3056, 2011 | 2 | 2011 |
| Impact of handling missing PK data on PD estimation–explicit modeling of BLQ data in WinBUGS® reduced bias in the PD predictions–a preclinical example C Dartois, M Looby, H He, JL Steimer, G Pillai | 2 | 2007 |
| Mathematical modeling of patient-level hemoglobin delineates ruxolitinib’s complex mechanism of action and quantifies anemia risk C Sarr, S Urva, J Nedelman, W Sallas, V Stalbovskaya, P Gopalakrishna, ... Blood 124 (21), 3228-3228, 2014 | 1 | 2014 |
| Hyperglycemia in patients treated with the pan-PI3K inhibitor buparlisib (BKM120): characterization, management, and assessment for pharmacodynamics A Azaro, J Rodon, JF Vansteenkiste, Y Ando, T Doi, D Mills, C Sarr, ... EUROPEAN JOURNAL OF CANCER 49, S186-S186, 2013 | 1 | 2013 |
| Population PK-PD Modeling of Everolimus in the Treatment of Patients with Tuberous Sclerosis Complex (TSC) Who Have Subependymal Giant Cell Astrocytomas (SEGA) W Sallas, O Chiparus, W Cheung, S Urva, J Wang, H Cauwel, D Lam, ... JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS 40, S40-S41, 2013 | 1 | 2013 |
| The Standard Output (SO): A Tool‐Agnostic Modeling Storage Format N Terranova, MK Smith, R Nordgren, E Comets, M Lavielle, K Harling, ... CPT: pharmacometrics & systems pharmacology, 2018 | | 2018 |
